Senzime — Share Issue/Capital Change 2023

Jul 14, 2023

PRESS RELEASE 14 July 2023 12:15:00 CEST

Outcome of directed share issue to sellers of Respiratory Motion

Press release: Uppsala, July 14, 2023

The Board of Directors of Senzime AB (publ) ("Senzime") has, based on the authorization to issue shares granted by the general meeting on May 16, 2023 and as previously announced through a press release, resolved on July 5, 2023 on a directed issue of shares to sellers of Respiratory Motion, Inc. The directed share issue has been fully subscribed and in accordance with the Board of Directors' resolution, 5,055,954 shares were subscribed and allocated during the subscription period.

For further information, please contact:

Philip Siberg, CEO of Senzime AB Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDAcleared patient monitoring systems. Senzime's employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Outcome of directed share issue to sellers of Respiratory Motion